Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.16
$0.11(1.56%)
At close: 4:00 PM EDT
$7.16
$0.11(1.56%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous Close$7.16
Volume252.14K
Average Volume (3M)616.86K
Market Cap
$793.34M
Enterprise Value$366.28
Total Cash (Recent Filing)$323.84M
Total Debt (Recent Filing)$16.59M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 05, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding103,704,810
10 Day Avg. Volume397,740
30 Day Avg. Volume616,855
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.50Price Target Upside186.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical Progress (Phase 3, SPA)Completion of Phase 3 enrollment under an FDA Special Protocol Assessment materially reduces regulatory design risk and timing uncertainty. This increases the probability that bel-sar can advance toward approval as a frontline, vision-preserving ocular therapy, improving long-term commercial prospects if efficacy is confirmed.
Extended Cash Runway After RestructuringCost structure actions that extend runway into 1H 2029 give Aura more time to reach Phase 3 topline (H2 2027) and pursue regulatory milestones without immediate financing. That structural extension lowers near-term financing pressure and provides a clearer path to value-driving clinical readouts.
Strengthened Leadership And Board Commercialization ExperienceAdding experienced directors and senior executives with proven commercialization and rare oncology transaction experience enhances governance and execution capacity. This durable improvement in leadership quality supports strategic planning for registration, launch readiness, and potential partnering or M&A outcomes.
Bears Say
No Revenue And Widening Net LossesAs a clinical-stage biotech, Aura lacks product revenue while net losses have materially increased. Persistent negative earnings mean the business cannot self-fund development or commercialization, raising structural dependence on external capital and increasing medium-term execution risk if clinical outcomes delay or fail.
Sustained High Cash Burn And Negative Operating Cash FlowRising cash burn and materially negative operating cash flow are durable constraints on flexibility. Even with a reasonable balance sheet today, continued high outflows force repeated capital raises or partnerships, increase dilution risk, and can limit ability to fund parallel programs or commercial infrastructure long-term.
Expanded Share Authorization Raises Dilution CapacityTripling authorized shares structurally increases the company’s ability to issue equity for cash, deals, or compensation. While it supports financing flexibility, it also elevates medium-term dilution risk, which is significant given ongoing losses and potential future equity financings for late-stage development or commercialization.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $793.34M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Nov 05, 2026 which is in 81 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Aug 11, 2026. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.105.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.37.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,704,810 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 4.416%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (186.31% Upside)
$20.50 (186.31% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 83.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
70.32%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA Stock 12 Month Forecast
Average Price Target
$20.50
▲(186.31% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.19% Insiders
5.21% Mutual Funds
66.33% Other Institutional Investors
17.45% Public Companies and
Individual Investors